Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 141 No. 3940 (2011)

Psychotropic medication use in Swiss nursing homes

  • I Lustenberger
  • B Schüpbach
DOI
https://doi.org/10.4414/smw.2011.13254
Cite this as:
Swiss Med Wkly. 2011;141:w13254
Published
26.09.2011

Summary

BACKGROUND: Psychotropic medication is commonly used in nursing homes, to treat behavioural and psychological symptoms of dementia (BPSD) for example. Treatment with antipsychotics may improve BPSD in some residents but can be associated with serious side effects, such as higher mortality, faster disease progression and cerebrovascular events. In the current study, psychotropic medication use was analysed in a representative sample of nursing home residents in the German-speaking part of Switzerland, at entry and during follow-up.

METHODS: Retrospective analysis of the Resident Assessment Instrument Minimum Data Set (RAI-MDS) of 90 nursing homes at entry (n = 18853) and during follow-up (n = 12101).

RESULTS: At entry, 7580 residents (40.2%) were diagnosed with dementia and 49.0% of them had behavioural symptoms. Residents with dementia received more psychotropic medication than residents without dementia (70.8% vs. 55.0%; p<0.001). The most commonly prescribed medications were antipsychotics (demented 44.8% vs. non-demented 17.4%; p<0.001) and antidepressants (demented 29.6% vs. non-demented 26.7%; p<0.001). Antipsychotics were mainly prescribed for residents with dementia and behavioural disturbances. The longitudinal analysis revealed that most residents with dementia (69.5%) took antipsychotics continuously from entry to the final assessment and the same was true for antidepressants (66.1%). The use of antipsychotics at baseline in residents with dementia predicted (p<0.001) the use of antipsychotics during follow-up.

CONCLUSIONS: The long term use of antipsychotics in nursing homes may need to be reconsidered in view of novel treatment recommendations, suggesting that the prescription of antipsychotics for patients with dementia should be a second line treatment, restricted to symptoms of psychosis or severe aggression, and prescribed for the shortest duration possible.

References

  1. Matthews FE, Dening T. Prevalence of dementia in institutional care. Lancet. 2002;360(9328):225–6.
  2. Kramer D, Allgaier AK, Fejtkova S, Mergl R, Hegerl U. Depression in nursing homes: prevalence, recognition, and treatment. Int J Psychiatry Med. 2009;39(4):345–58.
  3. Testad I, Aasland AM, Aarsland D. Prevalence and correlates of disruptive behavior in patients in Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22(9):916–21.
  4. Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr. 2010;22(7):1025–39.
  5. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(Suppl 3):497–500.
  6. Alanen HM, Finne-Soveri H, Noro A, Leinonen E. Use of antipsychotics among nonagenarian residents in long-term institutional care in Finland. Age Ageing. 2006;35(5):508–13.
  7. Snowdon J, Day S, Baker W. Current use of psychotropic medication in nursing homes. Int Psychogeriatr. 2006;18(2):241–50.
  8. Gobert M, D’Hoore W. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland. Int J Geriatr Psychiatry. 2005;20(8):712–21.
  9. Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22(9):843–9.
  10. Hosia-Randell H, Pitkala K. Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland. Drugs Aging. 2005;22(9):793–800.
  11. Pitkala KH, Laurila JV, Strandberg TE, Tilvis RS. Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards. Int Psychogeriatr. 2004;16(1):61–74.
  12. Mann E, Kopke S, Haastert B, Pitkala K, Meyer G. Psychotropic medication use among nursing home residents in Austria: a cross-sectional study. BMC Geriatr. 2009;9:18.
  13. Nijk RM, Zuidema SU, Koopmans RT. Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. Int Psychogeriatr. 2009;21(3):485–93.
  14. Feng Z, Hirdes JP, Smith TF, Finne-Soveri H, Chi I, Du Pasquier JN, et al. Use of physical restraints and antipsychotic medications in nursing homes: a cross-national study. Int J Geriatr Psychiatry. 2009;24(10):1110–8.
  15. Locca JF, Bula CJ, Zumbach S, Bugnon O. Pharmacological treatment of behavioral and psychological symptoms of dementia (BPSD) in nursing homes: development of practice recommendations in a Swiss canton. J Am Med Dir Assoc. 2008;9(6):439–48.
  16. Locca JF, Ruggli M, Buchmann M, Huguenin J, Bugnon O. Development of pharmaceutical care services in nursing homes: practice and research in a Swiss canton. Pharm World Sci. 2009;31(2):165–73.
  17. Nishtala PS, McLachlan AJ, Bell JS, Chen TF. Psychotropic prescribing in long-term care facilities: impact of medication reviews and educational interventions. Am J Geriatr Psychiatry. 2008;16(8):621–32.
  18. Eggermont LH, de Vries K, Scherder EJ. Psychotropic medication use and cognition in institutionalized older adults with mild to moderate dementia. Int Psychogeriatr. 2009;21(2):286–94.
  19. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
  20. Rochon PA, Normand SL, Gomes T, Gill SS, Anderson GM, Melo M, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168(10):1090–6.
  21. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.
  22. Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009;70(10):1340–7.
  23. Hartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci. 2007;62(10):1172–81.
  24. Jalbert JJ, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc. 2010;11(2):120–7.
  25. Kong EH, Evans LK, Guevara JP. Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis. Aging Ment Health. 2009;13(4):512–20.
  26. Kozman MN, Wattis J, Curran S. Pharmacological management of behavioural and psychological disturbance in dementia. Hum Psychopharmacol. 2006;21(1):1–12.
  27. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608.
  28. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957–70.
  29. Anliker M, Bartelt G, Garms-Homolova V, Gilgen R, Staudenmeier B, Weiss U. RAI-Handbuch. Gesamtausgabe Version 2.0. St. Gallen: Q-Sys AG; 2000.
  30. von Gunten A, Mosimann UP. Delirium upon admission to Swiss nursing homes: a cross-sectional study. Swiss Med Wkly. 2010;140(25-26):376–81.
  31. Morris JN, Fries BE, Bernabei R, Steek K, Ikegami N, Carpenter I, et al. Long term care resident assessment instrument. User's manual version 2.0. InterRai; 1996.
  32. Anliker M. Erfahrungen mit RAI in den Alters- und Pflegeheimen der Schweiz. Printernet. 2007;9(5):332–5.
  33. Azermai M, Elseviers M, Petrovic M, Van Bortel L, Stichele RV. Geriatric drug utilisation of psychotropics in Belgian nursing homes. Hum Psychopharmacol. 2011.
  34. Molinari V, Chiriboga D, Branch LG, Cho S, Turner K, Guo J, et al. Provision of psychopharmacological services in nursing homes. J Gerontol B Psychol Sci Soc Sci. 2010;65B(1):57–60.
  35. Shah SM, Carey IM, Harris T, Dewilde S, Cook DG. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry. 2011;26(4):423–34.
  36. Nishtala PS, McLachlan AJ, Bell JS, Chen TF. Determinants of antipsychotic medication use among older people living in aged care homes in Australia. Int J Geriatr Psychiatry. 2010;25(5):449–57.
  37. Alanen HM, Finne-Soveri H, Noro A, Leinonen E. Use of antipsychotic medications among elderly residents in long-term institutional care: a three-year follow-up. Int J Geriatr Psychiatry. 2006;21(3):288–95.
  38. Macdonald AJ, Carpenter GI, Box O, Roberts A, Sahu S. Dementia and use of psychotropic medication in non-“Elderly Mentally Infirm” nursing homes in South East England. Age Ageing. 2002;31(1):58–64.
  39. Nobili A, Pasina L, Trevisan S, Riva E, Lucca U, Tettamanti M, et al. Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. International Clinical Psychopharmacology. 2009;24(2):97–104.
  40. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65(Suppl 2):5–99; discussion 100–102; quiz 103–4.
  41. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf. 2010.
  42. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7(6):492–500.
  43. Schaufele M, Bickel H, Weyerer S. Which factors influence cognitive decline in older adults suffering from dementing disorders? Int J Geriatr Psychiatry. 2002;17(11):1055–63.
  44. Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633–7.
  45. Ballard C, Grace J, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet. 1998;351(9108):1032–3.
  46. Lawlor BA. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J Clin Psychiatry. 2004;65(Suppl 11):5–10.
  47. Frank L, Kleinman L, Ciesla G, Rupnow MF, Brodaty H. The effect of risperidone on nursing burden associated with caring for patients with dementia. J Am Geriatr Soc. 2004;52(9):1449–55.
  48. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996–2021.
  49. Aupperle P. Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. Am J Alzheimers Dis Other Demen. 2006;21(2):101–8.
  50. Gruber-Baldini AL, Zimmerman S, Boustani M, Watson LC, Williams CS, Reed PS. Characteristics associated with depression in long-term care residents with dementia. Gerontologist. 2005;45 Spec No 1(1):50–5.
  51. Cohen CI, Hyland K, Kimhy D. The utility of mandatory depression screening of dementia patients in nursing homes. Am J Psychiatry. 2003;160(11):2012–7.
  52. Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15(11):942–52.
  53. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245–55.
  54. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(3):169–83.